FIG. 2.

Metformin therapy affects (A) serum carbohydrate antigen 199 (CA199) levels and (B) the incidence of high serum CA199 concentrations in the three groups at baseline and (C) the decreasing percentage of CA199 levels and (D) the high CA199 proportions of the three groups after 1 year of follow-up. (A) ^aP<0.05, ^bP<0.01 versus males; ^cP<0.01 versus females of the non-metformin group; ^dP<0.01 versus males of the non-metformin group; ^eP<0.01 versus males of the metformin group; ^fP<0.01 versus the total of the non-metformin group; ^gP<0.05 versus the total of the short-term metformin group. (B) ^hP<0.05, ⁱP<0.01 versus females; ^jP<0.01 versus males of the non-metformin group; ^kP<0.01 versus females of the non-metformin group; ^lP<0.01 versus females of the short-term metformin group; ^mP<0.01 versus the total of the non-metformin group; ⁿP<0.05 versus the total of the non-metformin group. (C) ^oP<0.05, ^qP<0.01 versus females of the non-metformin group; ^rP<0.05 versus females of the short-term metformin group; ^sP<0.05, ^tP<0.01 versus the total of the non-metformin group. (D) ^uP<0.05 versus females of the non-metformin group; ^vP<0.05 versus the total of the non-metformin group.